Data-driven analysis backed by 1,400+ primary-sourced biopharma transactions. Licensing benchmarks, negotiation strategies, and market intelligence.
Ipsen has executed 8 deals since 2017, with a sharp pivot toward hematology driving its most recent — and largest — transactions. Here's what their deal activity tells BD teams, founders, and investors about where Ipsen is heading and how to position assets accordingly.
Mega-deal activity exploded from zero to 61 transactions between February and August 2026 — a 6100% increase period over period. Eli Lilly, GSK, and Boehringer Ingelheim are leading the charge. Here's what's driving the surge and what it means for your next negotiation.
Deal activity in the 'other' modality category exploded by 1271% in the first half of 2026, jumping from 7 deals to 96. AstraZeneca's $18.5B total deal value with CSPC Pharmaceutical and Novo Nordisk's $2.4B Omeros deal signal a structural shift in what pharma is willing to pay for unconventional assets.
Hematology licensing activity jumped from zero deals to 17 in six months — a 1700% surge that rewrites the competitive map. The Incyte-Vega Therapeutics deal alone carries a $2B total deal value. Here's what's driving the trend and what it means for your next term sheet.
Vaccine deal activity exploded from zero transactions to 17 in six months — a 1700% surge driven by Big Pharma pipeline anxiety and next-gen platform bets. Eli Lilly and Sanofi are leading the charge with multi-billion-dollar deals that are resetting valuation benchmarks across the modality.
ADC licensing activity exploded 1900% in six months, jumping from 1 deal to 20. GSK, Novartis, and others are paying up aggressively — here's what's driving the surge and what it means for your next negotiation.
Other deal activity surged 3000% in the first half of 2026, jumping from zero recorded transactions to 30 in six months. Megadeals from Merck KGaA and Pfizer are redefining what counts as a licensing target — and BD teams need to recalibrate fast.
Small molecule deal activity exploded from 3 transactions to 95 in a single six-month window — a 3067% increase. The data points to a fundamental repricing of small molecule assets as Big Pharma races to fill post-LOE pipeline gaps.
Rare disease deal activity exploded from 1 transaction to 35 in six months — a 3400% increase. Five deals north of $1.9B in total deal value closed in a single two-week window in June 2026. Here's what's driving it and what BD teams need to do now.
Mega-deal activity exploded from zero to 61 transactions in six months — a 6100% increase. With Eli Lilly, GSK, and Boehringer Ingelheim all making billion-dollar moves in July alone, this isn't a blip. Here's the data, the drivers, and what it means for your next negotiation.
Roche has committed $190M to license Hanmi Pharmaceutical's lean-mass preservation obesity asset — paying above-median upfront by Phase 2 metabolic licensing standards and signaling that muscle-sparing biology is now a formal portfolio priority. We break down where this deal sits against current benchmarks, how it compares to Roche's own recent metabolic transactions, and what it means for dealmakers with similar assets in play.
Hematology licensing activity exploded from zero deals to 16 in six months — a 1600% surge that signals a fundamental shift in Big Pharma pipeline strategy. The Incyte-Vega $2B TDV deal is the clearest proof point. Here's what BD teams need to know right now.
Vaccine licensing activity exploded from zero deals to 17 in six months — a 1700% surge that marks the sharpest modality-level spike in biopharma dealmaking this year. Eli Lilly and Sanofi are leading the charge with multi-billion-dollar structures that reset valuation benchmarks.
ADC licensing activity exploded 1900% in the first half of 2026, jumping from 1 deal to 20 in a single six-month window. Novartis, GSK, and a wave of mid-cap buyers are driving the frenzy — and deal structures are shifting fast.
Small molecule deal activity exploded from 3 deals to 95 in six months — a 3067% increase. The surge is reshaping small molecule licensing 2026 dynamics, and BD teams need to recalibrate expectations on structure, upfronts, and competitive timelines.
Rare disease licensing activity exploded from 1 deal to 35 deals in six months — a 3400% increase. Five transactions alone carried total deal values above $1.9B each. Here's what's driving the surge and what it means for your next negotiation.
Deal activity in non-traditional therapeutic categories exploded 3400% in the first half of 2026, jumping from zero transactions to 34 in six months. The Bio-Techne/Merck KGaA $11.3B acquisition and Pfizer's $2B YaoPharma licensing deal signal a fundamental shift in where Big Pharma is placing its bets.
Mega-deal activity surged 6100% in the first half of 2026, jumping from zero transactions to 61 in a single six-month window. Eli Lilly alone accounted for $4.7B in total deal value across two licensing plays in a single week. Here's what's driving the spike and what it means for your next negotiation.
Bayer has executed 13 deals since 2019, with a 24.5% average upfront ratio and a clear tilt toward cardiovascular, metabolic, and women's health assets. Here's what the pattern reveals about their pipeline thesis and what it means if you're pitching them.
Eli Lilly and Company executed 14 deals between January and July 2026, with a 3.4% average upfront ratio and heavy concentration in platform-scale acquisitions. Here's what their deal flow tells us about where Lilly is headed — and what it means if you're on the other side of the table.
Deal activity in the 'other' modality category exploded by 1271% between H2 2025 and H1 2026, jumping from 7 transactions to 96. The Omeros–Novo Nordisk and CSPC–AstraZeneca megadeals signal that Big Pharma is hunting outside traditional modality lanes — and paying up for it.
Hematology deal activity jumped 1600% in the first half of 2026, going from zero recorded deals to 16 in a single six-month window. The Incyte–Vega Therapeutics transaction alone carried a $2B total deal value. Here's what's driving the surge and what it means for BD teams negotiating hematology licensing in 2026.
Vaccine licensing went from zero recorded deals to 17 in six months — a 1700% spike that signals a structural shift in pharma pipeline strategy. Here's what's driving it and what BD teams should do about it.
ADC licensing activity exploded 1900% in six months, jumping from 1 deal to 20. GSK, Novartis, and Whitehawk are leading the charge. Here's what the data says and what it means for your next negotiation.
Small molecule licensing activity exploded by 3,067% in the first half of 2026, jumping from 3 deals to 95. Here's what's driving the surge, who's writing the biggest checks, and what BD teams should do about it right now.
Get data-driven deal terms for any therapeutic area, modality, and clinical phase. Powered by 1,400+ primary-sourced biopharma transactions.
Try Solidus
